HALO News and Press, Halozyme Therapeutics Inc. From 11/08/22

The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Halozyme Therapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation

Halozyme Therapeutics press release ( NASDAQ: HALO ): Q3 Non-GAAP EPS of $0.74 beats by $0.23 . Revenue of $208.98M (+80.4% Y/Y) beats by $17.81M . FY2022 Outlook : Total revenue of $655M to $685M vs. consensus of $661.35M; GAAP operating income of $24...

HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS PR Newswire Third Quarter Revenue Increased 80% YOY to $209 Million , with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.74 1 Record Thi...

Halozyme to Report Third Quarter 2022 Financial and Operating Results PR Newswire SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2022 financial and operat...

Summary Halozyme made a smooth transition from a failed R&D company to a successful royalty company. Their Antares acquisition is a bid to delay ENHANZE IP expiry, although the autoinjector platform is no real replacement for ENHANZE. However, for the next few years, HALO ...

Summary The new Halozyme is well-fixed to grow revenues from multiple sources over the balance of this decade and beyond. Halozyme's effective execution of its business model substantially reduces its risk profile compared to other pharmas. Halozyme's recent acquisition of Ant...

Last week’s political and financial shenanigans in the UK coupled with unusual volatility in US equities made for challenging trading conditions, writes Ian Murphy of MurphyTrading.com. For further details see: Challenging Conditions

Halozyme to Participate in the 2022 Wells Fargo Healthcare Conference PR Newswire SAN DIEGO , Sept. 1, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executive o...

Halo Collective Inc. (NEO: HALO) (OTCQB: HCANF) posted mostly positive results with revenues ticking up over the quarter — illustrating the west-coast operator’s pursuit to shave losses and pay down debt. The company announced its financial results for the first ...

Halozyme Therapeutics ( NASDAQ: HALO ) has priced upsized offering of $625M of 1.00% convertible senior unsecured notes due  August 15, 2028. The offering was upsized from an originally announced $500M. Initial purchasers granted an option to purchase up...